Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The parameters below describe how it is used in supervised clinical care they are not a recommendation to self-administer, and we do not publish dosing for unsupervised use
Results of this small pilot study suggest that treatment with autologous thymosin 4 (T4) prior to endothelial progenitor cell in STEMI patients may be associated with improved left ventricular function and exercise capacity at six months post-procedure
90% of people who get affected by this condition do not hail from an athletic background
Sources & References 1RPEP-13892Vasireddi, Nikhil et al
Sources FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks International Journal of Molecular Sciences: From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Modulation PubMed: Thymosin 4: Potential to Treat Epidermolysis Bullosa and Other Severe Dermal Injuries Europe PMC: Thymosin beta4 Enhances Repair by Organizing Connective Tissue and Preventing the Appearance of Myofibroblasts WADA: The Prohibited List FDA: BeSafeRx Your Source for Online Pharmacy Information MedlinePlus: Talking With Your Doctor Medically reviewed by Dr
Timing Baseline Marker Comprehensive metabolic panel (CMP) Why it matters Reviews liver enzymes, kidney markers, electrolytes, and glucose in one broad safety panel
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
